GlassScriptPhysician profile
John T Stewart
NPI 1417031022
$7,040.76
in general payments reported to CMS, 2019-2025
46 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $504 · 2021: $728 · 2022: $1,235 · 2023: $1,517 · 2024: $1,294 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,169.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $846.75 | 2019-2025 | Vraylar |
| Lilly USA, LLC | $810.61 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $656.18 | 2021-2025 | |
| Glaxosmithkline, LLC. | $579.10 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $318.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Almatica Pharma LLC | $286.35 | 2021-2024 | Loreev Xr, Gralise, Teriparatide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.40 | 2020-2025 | Jardiance |
| Mannkind Corporation | $247.73 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $241.72 | 2022-2025 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.53 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $192.39 | 2023-2024 | Gemtesa, Aptiom |
| Merck Sharp & Dohme LLC | $185.96 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Astrazeneca Pharmaceuticals LP | $184.16 | 2019-2025 | Breztri |
| Sunovion Pharmaceuticals INC. | $179.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $176.50 | 2022-2024 | Leqvio |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.